Related Experiment Video
Updated: Jun 28, 2025
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
Precision nanomedicine to treat non-small cell lung cancer
Akanksha Dessai1, Usha Yogendra Nayak1, Yogendra Nayak2
1Department of Pharmaceutics, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka 576104, India.
Abstract:
Lung cancer is a major cause of death worldwide, being often detected at a later stage due to the non-appearance of early symptoms. Therefore, specificity of the treatment is of utmost importance for its effective treatment. Precision medicine is a personalized therapy based on the genomics of the patient to design a suitable drug approach. Genetic mutations render the tumor resistant to specific mutations and the therapy is in vain even though correct medications are prescribed. Therefore, Precision medicine needs to be explored for the treatment of Non-small cell lung cancer (NSCLC). Nanoparticles are widely explored to give personalized interventions to treat lung cancer due to their various advantages like the ability to reach cancer cells, enhanced permeation through tissues, specificity, increased bioavailability, etc. Various nanoparticles (NPs) including gold nanoparticles, carbon nanotubes, aptamer-based NPs etc. were conjugated with biomarkers/diagnostic agents specific to cancer type and were delivered. Various biomarker genes have been identified through precision techniques for the diagnosis and treatment of NSCLC like EGFR, RET, KRAS, ALK, ROS-1, NTRK-1, etc. By incorporating of drug with the nanoparticle through bioconjugation, the specificity of the treatment can be enhanced with this revolutionary treatment. Additionally, integration of theranostic cargos in the nanoparticle would allow diagnosis as well as treatment by targeting the site of disease progression. Therefore, to target NSCLC effectively precision nanomedicine has been adopted in recent times. Here, we present different nanoparticles that are used as precision nanomedicine and their effectiveness against NSCLC disease.
Insights
Precision nanomedicine offers targeted Non-small cell lung cancer (NSCLC) treatment. Nanoparticles deliver personalized therapies by targeting specific genetic mutations, improving drug efficacy and patient outcomes.
Area of Science:
- Oncology
- Nanotechnology
- Genomics
Background:
- Lung cancer, particularly Non-small cell lung cancer (NSCLC), is a leading cause of mortality often diagnosed late.
- Treatment specificity is crucial for effective NSCLC management, as genetic mutations can confer resistance to conventional therapies.
- Precision medicine, guided by patient genomics, offers a personalized approach to drug development.
Purpose of the Study:
- To explore the application of precision nanomedicine for the effective treatment of Non-small cell lung cancer (NSCLC).
- To review various nanoparticles utilized in precision nanomedicine for NSCLC and assess their therapeutic effectiveness.
Main Methods:
- Nanoparticles (NPs) like gold nanoparticles and carbon nanotubes were conjugated with cancer-specific biomarkers.
- Biomarker genes (e.g., EGFR, KRAS, ALK) identified through precision techniques were targeted.
- Drugs were incorporated into nanoparticles via bioconjugation to enhance treatment specificity.
- Theranostic cargos were integrated into NPs for simultaneous diagnosis and treatment.
Main Results:
- Nanoparticles demonstrate advantages for lung cancer treatment, including targeted delivery, enhanced permeation, and increased bioavailability.
- Bioconjugation of drugs with NPs improves treatment specificity against NSCLC.
- Theranostic NPs enable combined diagnostic and therapeutic capabilities for disease progression monitoring.
Conclusions:
- Precision nanomedicine represents a revolutionary approach for targeting NSCLC.
- The integration of nanotechnology and precision medicine enhances therapeutic specificity and efficacy for NSCLC.
- Nanoparticle-based precision therapies hold significant promise for improving outcomes in Non-small cell lung cancer patients.
More Related Videos
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
